Critical Comparison: Miravant Medical Technologies (OTCMKTS:MRVT) versus Vaxart (OTCMKTS:VXRT)

Miravant Medical Technologies (OTCMKTS:MRVT) and Vaxart (OTCMKTS:VXRT) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Miravant Medical Technologies and Vaxart’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Miravant Medical Technologies	N/A	N/A	N/A
Vaxart	15.88%	53.04%	20.85%

Institutional and Insider Ownership

18.0% of Vaxart shares are owned by institutional investors. 17.1% of Miravant Medical Technologies shares are owned by insiders. Comparatively, 2.8% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Miravant Medical Technologies and Vaxart, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Miravant Medical Technologies	0	0	0	0	0.00
Vaxart	0	1	0	0	2.00

Given Miravant Medical Technologies’ higher possible upside, equities research analysts clearly believe Miravant Medical Technologies is more favorable than Vaxart.

Earnings & Valuation

This table compares Miravant Medical Technologies and Vaxart”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Miravant Medical Technologies	N/A	N/A	N/A	N/A	N/A
Vaxart	$47.40 million	2.58	$16.33 million	$0.16	3.15

Vaxart has higher revenue and earnings than Miravant Medical Technologies.

Summary

Vaxart beats Miravant Medical Technologies on 6 of the 8 factors compared between the two stocks.

About Miravant Medical Technologies

Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors. Miravant Medical Technologies Inc. was formerly known as PDT, Inc. and changed its name to Miravant Medical Technologies Inc. in September 1997. The company was founded in 1989 and is headquartered in Santa Barbara, California.

About Vaxart

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.